Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 19, 2010, Pages 5793-5798

  Ahn, Yu Mi ^a   Clare, Michael ^a   Ensinger, Carol L ^a   Hood, Molly M ^a   Lord, John W ^a   Lu, Wei Ping ^a   Miller, David F ^a   Patt, William C ^a   Smith, Bryan D ^a   Vogeti, Lakshminarayana ^a   Kaufman, Michael D ^a   Petillo, Peter A ^a   Wise, Scott C ^a   Abendroth, Jan ^b   Chun, Lawrence ^b   Clark, Robin ^b   Feese, Michael ^c   Kim, Hidong ^b   Stewart, Lance ^b   Flynn, Daniel L ^a  

^a Deciphera Pharmaceuticals LLC   (United States)

^b Emerald BioStructures   (United States)

^c Cocrystal Discovery Inc ^*  (United States)

Author keywords

Arthritis; MAP kinase inhibitor; p38 kinase inhibitor; Switch contol inhibitor; Type II kinase inhibitor

Indexed keywords

ADENOSINE TRIPHOSPHATE; ARGININE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR;

ARTICLE; BINDING AFFINITY; CONFORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HINGE REGION; HUMAN; HUMAN CELL; X RAY CRYSTALLOGRAPHY;

ADENOSINE TRIPHOSPHATE; BINDING SITES; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; HELA CELLS; HUMANS; KINETICS; MITOGEN-ACTIVATED PROTEIN KINASE 14; PHENYLUREA COMPOUNDS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PYRAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77957552568     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.07.134     Document Type: Article

References (11)

1. Q.-Q. Xie, H.-Z. Xie, J.-X. Ren, L.-L. Li, and S.-Y. Yang J. Mol. Graphics Modell. 276 2009 751
2. C. Zhang, and G. Bollag Curr. Opin. Genet. Dev. 20 2010 79
3. T. Schindler, W. Bornmann, P. Pellicena, W.T. Miller, B. Clarkson, and J. Kuriyan Science 289 2000 1938
4. C. Pargellis, L. Tong, L. Churchill, P.F. Cirillo, T. Gilmore, A.G. Graham, P.M. Grob, E.R. Hickey, N. Moss, S. Pav, and J. Regan Nat. Struct. Biol. 9 2002 268
5. M. Huse, and J. Kuriyan Cell 109 2002 275
6. C. Dominguez, D.A. Powers, and N. Tamayo Curr. Opin. Drug Discovery Dev. 8 2005 421
7. Flynn, D. L.; Petillo, P. A. WO2004061084, WO2007008917, US20080248548.
8. Bellon, S.; Fitzgibbon, M. J.; Fox, T.; Wilson, K. P. Structure 1999, 7, 1057. Note that p38-alpha numbering is used in Figure 1A. The 1CM8 structure of p38-gamma has three additional N-terminal amino acids compared to p38-alpha. Hence, Arg70 in p38-alpha is equivalent to Arg73 in p38-gamma.
9. J. Regan, S. Breitfelder, P. Cirillo, T. Gilmore, A.G. Graham, E. Hickey, B. Klaus, J. Madwed, M. Moriak, N. Moss, C. Pargellis, S. Pav, A. Proto, A. Swinamer, L. Tong, and C. Torcellini J. Med. Chem. 45 2002 2994
10. J. Morrison, and C. Walsh Adv. Enzymol. Relat. Areas Mol. Biol. 61 1988 201
11. M.A. Fabian, W.H. Biggs III, D.K. Treiber, and C.E. Atteridge Nat. Biotechnol. 23 2005 329